DKSH Korea says MOHW expands Romiplate reimbursement for first-line severe aplastic anemia treatment

• DKSH Korea secured expanded reimbursement for Romiplate as a first-line severe aplastic anemia treatment, effective Aug. 1, 2026.
• Coverage now includes romiplostim with standard immunosuppressive therapy in treatment-naïve patients, widening access beyond prior second-line reimbursement limits.
• Change could lift near-term uptake in Korea by moving reimbursed use earlier in the treatment pathway for eligible severe aplastic anemia patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DKSH Holding AG published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.